Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 95.12 0.33 0.35% |
On a scale of 0 to 100, ANI Pharmaceuticals holds a performance score of 17. The firm shows a Beta (market volatility) of 0.84, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ANI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ANI Pharmaceuticals is expected to be smaller as well. Please check ANI Pharmaceuticals' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether ANI Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ANI Pharmaceuticals are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Even with relatively abnormal forward indicators, ANI Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.35 | Five Day Return 5.36 | Year To Date Return 71.57 | Ten Year Return 141.18 | All Time Return (55.50) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | Disposition of 47010 shares by Shanmugam Muthusamy of ANI Pharmaceuticals at 89.48 subject to Rule 16b-3 | 08/14/2025 |
2 | ANI Pharmaceuticals, Inc. Hits Fresh High Is There Still Room to Run | 08/22/2025 |
3 | Acquisition by Haughey Thomas of 4336 shares of ANI Pharmaceuticals subject to Rule 16b-3 | 08/29/2025 |
4 | INCY Announces New Late-Stage Data on Skin Disease Drug | 09/17/2025 |
5 | Disposition of 52990 shares by Shanmugam Muthusamy of ANI Pharmaceuticals at 87.15 subject to Rule 16b-3 | 09/19/2025 |
6 | HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal | 09/25/2025 |
7 | AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinsons Disease | 09/29/2025 |
8 | Can ANI Pharmaceuticals Inc. stock deliver strong Q4 earnings - Market Activity Summary Free High Return Stock Watch Alerts - newser.com | 10/06/2025 |
9 | An Overview of Tilray Brandss Earnings | 10/08/2025 |
10 | BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers | 10/09/2025 |
11 | Disposition of 400 shares by Meredith Cook of ANI Pharmaceuticals at 90.09 subject to Rule 16b-3 | 10/13/2025 |
12 | Why ANI Could Beat Earnings Estimates Again | 10/15/2025 |
13 | ANI Upgraded to Strong Buy Heres Why | 10/16/2025 |
14 | NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs | 10/17/2025 |
| Begin Period Cash Flow | 221.1 M | |
| Total Cashflows From Investing Activities | -404.7 M |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 6,690 in ANI Pharmaceuticals on July 23, 2025 and sell it today you would earn a total of 2,822 from holding ANI Pharmaceuticals or generate 42.18% return on investment over 90 days. ANI Pharmaceuticals is currently generating 0.5954% in daily expected returns and assumes 2.7751% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than ANI, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2145
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANIP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.78 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.6 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 17 83% of assets perform better |
Based on monthly moving average ANI Pharmaceuticals is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding it to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | -0.0217 | ||||
| Return On Asset | 0.0109 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.41 B | ||||
| Shares Outstanding | 22.29 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 4.55 X | ||||
| Price To Sales | 2.84 X | ||||
| Revenue | 614.38 M | ||||
| Gross Profit | 456.39 M | ||||
| EBITDA | 79.15 M | ||||
| Net Income | (18.52 M) | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 624.09 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 21.70 X | ||||
| Cash Flow From Operations | 64.02 M | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 2.12 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | (100.28 M) | ||||
| Working Capital | 334 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 199.53 | 182.58 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Assets | (0.01) | (0.02) | |
| Return On Equity | (0.04) | (0.05) |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 614.38 M. Net Loss for the year was (18.52 M) with profit before overhead, payroll, taxes, and interest of 456.39 M. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.